PRA Health Sciences Inc (PRAH) Given Consensus Rating of “Hold” by Brokerages

Shares of PRA Health Sciences Inc (NASDAQ:PRAH) have earned a consensus rating of “Hold” from the thirteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $114.25.

PRAH has been the topic of several analyst reports. Robert W. Baird raised their target price on PRA Health Sciences from $119.00 to $122.00 and gave the company an “outperform” rating in a report on Thursday, February 28th. BidaskClub downgraded PRA Health Sciences from a “hold” rating to a “sell” rating in a report on Friday. Wolfe Research initiated coverage on PRA Health Sciences in a report on Tuesday, April 2nd. They set a “market perform” rating on the stock. ValuEngine downgraded PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Saturday, April 13th. Finally, SunTrust Banks lifted their price objective on PRA Health Sciences to $120.00 and gave the stock an “average” rating in a report on Monday, March 4th.

Several hedge funds and other institutional investors have recently modified their holdings of PRAH. Bank of New York Mellon Corp increased its holdings in shares of PRA Health Sciences by 12.2% in the 3rd quarter. Bank of New York Mellon Corp now owns 2,465,247 shares of the medical research company’s stock valued at $271,645,000 after acquiring an additional 268,243 shares during the last quarter. Standard Life Aberdeen plc increased its holdings in shares of PRA Health Sciences by 2.4% in the 3rd quarter. Standard Life Aberdeen plc now owns 132,834 shares of the medical research company’s stock valued at $14,637,000 after acquiring an additional 3,131 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of PRA Health Sciences by 56.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 120,190 shares of the medical research company’s stock valued at $13,244,000 after acquiring an additional 43,542 shares during the last quarter. LPL Financial LLC increased its holdings in shares of PRA Health Sciences by 34.7% in the 3rd quarter. LPL Financial LLC now owns 5,897 shares of the medical research company’s stock valued at $650,000 after acquiring an additional 1,520 shares during the last quarter. Finally, Deutsche Bank AG increased its holdings in shares of PRA Health Sciences by 2.7% in the 3rd quarter. Deutsche Bank AG now owns 112,937 shares of the medical research company’s stock valued at $12,442,000 after acquiring an additional 2,969 shares during the last quarter. Institutional investors and hedge funds own 98.14% of the company’s stock.

Shares of NASDAQ:PRAH traded down $0.89 during mid-day trading on Monday, hitting $93.58. 154,736 shares of the company traded hands, compared to its average volume of 532,444. The company has a market cap of $6.19 billion, a P/E ratio of 23.81, a PEG ratio of 1.36 and a beta of 1.12. The company has a debt-to-equity ratio of 1.03, a quick ratio of 0.87 and a current ratio of 0.87. PRA Health Sciences has a 52-week low of $79.20 and a 52-week high of $121.98.

About PRA Health Sciences

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Featured Story: What is a Leveraged Buyout (LBO)?

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.